Moreover, sorafenib, in combination with anti-CD38 and anti-GD2 antibodies, can significantly increase its effect on inhibiting the tumor (Huang et al., 2021; Müller et al., 2022; Theruvath et al., 2022). The gene discussed is CD38; the disease is neoplasm.